Skip to main content

Table 1 Study cohort characteristics

From: Phenylketonuria: reduced tyrosine brain influx relates to reduced cerebral protein synthesis

Patient Age (yrs) Phe tolerance (mg/kg/day) Plasma Phe (μmol/L) Plasma Tyr (μmol/L) k2,1a k3,2b k1,2c
1 16 28 233 66 0.055 1.06 0.073
2 23 11 358 37 0.037 0.48 0.064
3 23 12 361 32 0.046 0.71 0.077
4 24 16 373 35 0.041 0.46 0.070
5 26 31 375 47 0.031 0.50 0.052
6 25 27 405 49 0.031 0.47 0.069
7 23 20 411 87 0.037 0.70 0.072
8 21 18 477 31 0.034 0.42 0.061
9 22 32 546 42 0.033 0.54 0.057
10 25 13 565 76 0.028 0.78 0.047
11 20 19 586 38 0.039 0.55 0.085
12 24 17 632 61 0.023 0.50 0.055
13 21 15 805 35 0.027 0.36 0.066
14 27 23 825 49 0.021 0.32 0.060
15 47 14 1078 33 0.019 0.21 0.029
16 33 12 1362 37 0.021 0.34 0.049
  1. Phe tolerance values were obtained at age 5 years. Patients 15 and 16 were treated from 6 and 9 years of age onward, respectively. In these patients, Phe tolerance was determined 6 months after treatment start. Phenylalanine and tyrosine plasma concentrations shown are baseline values. a 11C-Tyr transport from blood to brain (ml plasma/g brain tissue/min). b11C-Tyr cerebral protein incorporation (nmol/g brain tissue/min). c11C-Tyr transport from brain to blood (ml plasma/g brain tissue/min).